Table 5.
Summary of abstracts on adrenocorticotropic hormone therapy in focal segmental glomerulosclerosis and minimal change disease
| Author | Number of patients | Immunosuppression response category | ACTH preparation | Total dose (per week) | Duration of treatment (months) | Follow-up duration (months) | CR | PR | NR | Early termination |
|---|---|---|---|---|---|---|---|---|---|---|
| Khastgir et al. [25]a | 2 | 2 IR | Natural | 160 U | >6 | >6 | 2 | 0 | 0 | 0 |
| Madan et al. [24]b | 8 | NA | Natural | 160 U | >6 | >6 | 2 | 3 | 3 | 1 |
| Berg et al. [22]c,d | 10 | NA | Synthetic | 2 mg | 18 (7–48) | 0–29e | 3 | 5 | 2 | 0 |
ACTH, adrenocorticotropic hormone; CR, complete response; IR, immunosuppression resistant (other than steroids); NA, data not available; NR, no response; PR partial response.
aResponse criteria were not provided.
bCR defined as urine protein excretion <500 mg/day; PR defined as >50% reduction of proteinuria and urine protein excretion <3.5 g/day.
cCR defined as urine protein excretion <200 mg/day; PR defined as >50% reduction of proteinuria and urine protein excretion <2 g/day.
dAll patients received other immunosuppressive agents concomitant with ACTH.
eMonths after ACTH discontinuation.